Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$20.29 USD

20.29
4,205,646

+0.72 (3.68%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $20.22 -0.07 (-0.34%) 7:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe

by Zacks Equity Research

Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.

Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks

by Zacks Equity Research

Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.

Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug

by Zacks Equity Research

Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.

Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls

by Zacks Equity Research

Verve (VERV) stops enrollment in the phase Ib study of gene therapy candidate VERVE-10 to reduce disease-driving low-density lipoprotein cholesterol due to safety issues. Stock plunges on the news.

Vanda (VNDA) Up on FDA Nod for Fanapt in Bipolar I Disorder

by Zacks Equity Research

Vanda (VNDA) announces the FDA's approval of Fanapt for the acute treatment of bipolar I disorder in adults. The stock rises 30.4%.

EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia

by Zacks Equity Research

The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.

Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data

by Zacks Equity Research

Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.

Here's Why Amgen (AMGN) Stock is Outperforming the Industry

by Zacks Equity Research

Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to make up for lower revenues from oncology biosimilars and Enbrel

Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion

by Zacks Equity Research

Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.

Disc Medicine (IRON) Down on Mixed Results From AURORA Study

by Zacks Equity Research

Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.

Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why

by Zacks Equity Research

Avalo (AVTX) surges on adding a new pipeline drug, which has its origins at Eli Lilly. Alongside the acquisition, it also secured funding to continue operations beyond 2027.

Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development

by Zacks Equity Research

Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.

Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug

by Zacks Equity Research

Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.

Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study

by Zacks Equity Research

Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.

AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance

by Zacks Equity Research

AstraZeneca's (AZN) BLA is seeking approval of Dato-DXd for previously treated metastatic HR-positive, HER2-negative breast cancer.

AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod

by Zacks Equity Research

FDA approves AstraZeneca's (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for treating extravascular hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria.

Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights

by Zacks Equity Research

In the most recent trading session, Adma Biologics (ADMA) closed at $6.54, indicating a -0.91% shift from the previous trading day.

Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study

by Zacks Equity Research

Patients treated with Bristol Myers' (BMY) Zeposia in a phase III study for Crohn's disease did not achieve disease remission.

Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus

by Zacks Equity Research

Kodiak (KOD) reports a wider-than-expected loss for fourth-quarter 2023. The company provides updates regarding its pipeline development plans.

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding

by Zacks Equity Research

Moderna (MRNA) posts data on three experimental vaccines and intends to advance them to late-stage studies. It also secures $750 million in funding from Blackstone to advance its influenza program.

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why

by Zacks Equity Research

Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.

Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA

by Zacks Equity Research

Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.

Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD

by Zacks Equity Research

Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.

Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up

by Zacks Equity Research

Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.